We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+5.62%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$16.5B
AUM Growth
+$861M
Cap. Flow
+$217M
Cap. Flow %
1.32%
Top 10 Hldgs %
30.08%
Holding
735
New
44
Increased
335
Reduced
212
Closed
49

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$60.1M
2
QCOM icon
Qualcomm
QCOM
+$53.4M
3
NU icon
Nu Holdings
NU
+$48.5M
4
AMZN icon
Amazon
AMZN
+$46.5M
5
BMA icon
Banco Macro
BMA
+$43.2M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$40.8M
2
ADBE icon
Adobe
ADBE
+$36.1M
3
VIPS icon
Vipshop
VIPS
+$33.1M
4
SBUX icon
Starbucks
SBUX
+$31.4M
5
LOW icon
Lowe's Companies
LOW
+$29.1M

Sector Composition

Rank Sector Weight
1 Technology 33%
2 Healthcare 27.47%
3 Financials 9.69%
4 Consumer Discretionary 7.72%
5 Industrials 6.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PGR icon
51
Progressive
PGR
$124B
$71.3M 0.43%
343,496
+138,788
+68% +$29M
WCN
52
Waste Connections
WCN
$42.8B
$70.8M 0.43%
403,506
-44,135
-10% -$7.38M
PEP icon
53
PepsiCo
PEP
$186B
$67.9M 0.41%
411,944
+19,772
+5% +$3.41M
COST icon
54
Costco
COST
$415B
$67.6M 0.41%
79,557
-2,472
-3% -$1.93M
ZTS icon
55
Zoetis
ZTS
$31.6B
$64.4M 0.39%
371,240
+59,943
+19% +$9.98M
NBIX icon
56
Neurocrine Biosciences
NBIX
$17.7B
$64.1M 0.39%
465,467
+149,783
+47% +$20.5M
TRMB icon
57
Trimble
TRMB
$12.3B
$62.5M 0.38%
1,117,425
+62,989
+6% +$3.64M
BIIB icon
58
Biogen
BIIB
$29.9B
$61.8M 0.37%
266,459
-583
-0.2% -$127K
CTAS icon
59
Cintas
CTAS
$82.4B
$60.1M 0.36%
343,388
+117,172
+52% +$20M
TJX icon
60
TJX Companies
TJX
$170B
$59.5M 0.36%
540,379
+136,589
+34% +$13.8M
BAC icon
61
Bank of America
BAC
$435B
$58.4M 0.35%
1,469,257
-176,004
-11% -$6.75M
TTEK icon
62
Tetra Tech
TTEK
$8.23B
$57.8M 0.35%
1,394,325
-170,425
-11% -$6.95M
MRNA icon
63
Moderna
MRNA
$21.5B
$57.2M 0.35%
482,052
+40,007
+9% +$5.06M
BNY
64
Bank of New York Mellon
BNY
$108B
$56.4M 0.34%
941,209
+160,478
+21% +$9.29M
BDX icon
65
Becton Dickinson
BDX
$43.1B
$56.3M 0.34%
241,017
+3,172
+1% +$747K
CMCSA icon
66
Comcast
CMCSA
$79.1B
$56M 0.34%
1,429,020
+142,823
+11% +$5.59M
ALTR
67
DELISTED
Altair Engineering Inc
ALTR
$55M 0.33%
560,565
+125,816
+29% +$11.1M
SPGI icon
68
S&P Global
SPGI
$126B
$53.7M 0.33%
120,485
-14,841
-11% -$6.37M
VEEV icon
69
Veeva Systems
VEEV
$30.3B
$53.5M 0.32%
292,208
+48,365
+20% +$9.6M
HLT icon
70
Hilton Worldwide
HLT
$74B
$52.8M 0.32%
242,051
-4,119
-2% -$846K
SYK icon
71
Stryker
SYK
$127B
$51.7M 0.31%
151,965
-39,030
-20% -$13.2M
MCK icon
72
McKesson
MCK
$98.5B
$50.8M 0.31%
86,934
-26,112
-23% -$14.5M
MRVL icon
73
Marvell Technology
MRVL
$174B
$50M 0.3%
715,520
+2,250
+0.3% +$158K
EQIX icon
74
Equinix
EQIX
$107B
$49.9M 0.3%
65,993
-11,385
-15% -$8.64M
KLAC icon
75
KLA
KLAC
$275B
$49.7M 0.3%
602,310
+96,950
+19% +$7.16M

Similar funds

Candriam SCA's Q2 2024 Portfolio in Review

As of Q2 2024, Candriam SCA held 735 positions worth $16.5B, up 5.5% from $15.6B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Candriam SCA's Q2 2024 filing shows 44 new, 335 increased, 212 reduced and 49 closed positions. Its largest new stake was Banco Macro: 754,200 shares worth $43.2M. The largest sale was Apple, an estimated $40.8M.

By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q2 2024 buy was Banco Macro: 754,200 shares worth $43.2M.
  • Candriam SCA added most to Eli Lilly in Q2 2024, an estimated $60.1M increase.
  • Candriam SCA's biggest Q2 2024 reduction was Apple, cutting an estimated $40.8M.
  • Candriam SCA fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $16.5M.
  • Candriam SCA's ten largest holdings make up 30% of its $16.5B portfolio in Q2 2024.
  • Candriam SCA opened 44 new positions and closed 49 in Q2 2024.
  • Candriam SCA's portfolio value rose 5.5% quarter-over-quarter to $16.5B.

Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.